# **MATTERS ARISING**

# Monitoring COPD patients systemic and bronchial eosinophilic inflammation in a 2-year follow-up: few concerns

Divya Balan<sup>1\*</sup> and Mohan K. Manu<sup>1</sup>

## Abstract

Monitoring COPD patients: systemic and bronchial eosinophilic inflammation in a 2-year follow-up" by Pignatti et al. provides valuable insights about changes in blood and sputum eosinophils in mild to moderate COPD patients and treatment outcomes. However, concerns arise regarding the accuracy of diagnosis of COPD in subjects with a significant bronchodilator response despite FEV1/FVC ≤ 70%. Although statistically significant differences in FEV1/FVC were observed, the clinical relevance needs scrutiny. Despite a clinically meaningful difference in FEV1 between ICStreated and untreated patients, the lack of statistical significance raises questions. Addressing these concerns will strengthen the study's reliability and interpretation.

## Dear Editor,

I am writing regarding the recent article titled " Monitoring COPD patients: systemic and bronchial eosinophilic inflammation in a 2-year follow-up" published in BMC Pulmonary Medicine, Article number: 247 (2024), authored by Pignatti et al.[1]. The prospective design of the study allows understanding the changes over time, providing data on disease progression and treatment outcomes. By examining both blood and sputum eosinophil levels, a comprehensive evaluation of eosinophilic inflammation in COPD is done. While the study presents valuable insights over a 2-year follow-up period, several points raise questions about the methodology and interpretation of results.

Firstly, the presence of a significant bronchodilator response in a subgroup of subjects, despite having FEV1/ FVC  $\leq$  70%, raises questions about the accuracy of COPD diagnosis or the potential presence of asthma-COPD overlap syndrome (ACOS) [2]. This subgroup might exhibit different inflammatory profiles or treatment responses, which could confound the study outcomes[3].

Secondly, while statistically significant differences in FEV1/FVC were observed at different time points, the actual magnitude of change in median values appears small. While the statistical analysis might detect differences, assessing whether these differences are meaningful from a clinical perspective is essential.

Moreover, the absolute difference in FEV1 between ICS-treated and untreated patients (0.055, -0.65mL, respectively) appears substantial and clinically meaningful, no statistical significance was found in this analysis. This discrepancy raises questions about the factors influencing the observed FEV1 difference. Possible explanations include the relatively small sample size, inherent variability within groups, or confounding variables like adherence to treatment, concurrent medications, or lifestyle factors (e.g., smoking status), could have affected the results [4]. Therefore, despite the apparent clinical significance of the FEV1 difference, caution must be exercised in interpreting these findings.



© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.



<sup>\*</sup>Correspondence:

Divya Balan

divya.balan@manipal.edu

<sup>&</sup>lt;sup>1</sup> Department of Respiratory Medicine, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, Karnataka 576104, India

In conclusion, there is need for careful consideration of methodological limitations and interpretation of results. Addressing these issues will enhance the robustness and reliability of the study findings.

#### Acknowledgements

Not applicable.

## Authors' contributions

Divya Balan (D.B) wrote the manuscript and Manu K Mohan (M.K.M) edited and supervised the manuscript.

Funding

None.

#### Data availability

No datasets were generated or analysed during the current study.

#### Declarations

**Ethics approval and consent to participate** Not applicable.

#### **Consent for publication**

Not applicable.

**Competing interests** The authors declare no competing interests.

Received: 29 May 2024 Accepted: 8 May 2025 Published online: 16 May 2025

#### References

- 1. Pignatti P, Visca D, Zappa M, Zampogna E, Saderi L, Sotgiu G, et al. Monitoring COPD patients: systemic and bronchial eosinophilic inflammation in a 2-year follow-up. BMC Pulm Med. 2024;24(1):247.
- Global Initiative for Chronic Obstructive Lung Disease GOLD. Asthma, COPD, and Asthma-COPD Overlap Syndrome. Available from: https:// goldcopd.org/asthma-copd-asthma-copd-overlap-syndrome/. Cited 2024 May 27.
- Kolsum Ü, Ravi A, Hitchen P, Maddi S, Southworth T, Singh D. Clinical characteristics of eosinophilic COPD versus COPD patients with a history of asthma. Respir Res. 2017;18:73.
- Chen H, Luo X, Du Y, He C, Lu Y, Shi Z, et al. Association between chronic obstructive pulmonary disease and cardiovascular disease in adults aged 40 years and above: data from NHANES 2013–2018. BMC Pulm Med. 2023;23(1):318.

### **Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.